Print

Print


Burnham medical researcher describes the challenge of brain illnesses
Robyn Shelton | Sentinel Medical Writer
September 11, 2008
They are some of the world's most vexing diseases: Alzheimer's, multiple 
sclerosis, Parkinson's and Lou Gehrig's.

Though treatments exist, better therapies are needed for the millions with 
these devastating afflictions. Enter Dr. Stuart Lipton, who spoke Wednesday 
in Orlando about common links among brain diseases and the potential to 
exploit them for treatments.

The catch: Doctors walk a fine line between shutting down destructive 
chemical processes in the brain and interfering with normal functions.

"The brain is a very strange and intricate place; you can't just muck 
around," said Lipton of the Burnham Institute for Medical Research in La 
Jolla, Calif. "The problem is most drugs work like a sledgehammer" when more 
subtle treatments are needed.

He is the third Burnham scientist to visit Central Florida as part of a 
lecture series about the group's work in cancer, infectious diseases, 
obesity, diabetes and other fields. The institute is constructing an $80 
million complex at Lake Nona, where local officials hope it will be a magnet 
for biomedical companies and high-paying jobs.

Until the campus is completed next year, scientists are working from donated 
offices and laboratories in Orlando.

"Burnham is really at the front . . . creating the kind of life-science 
research that could stimulate the economy," said Ed Baxa, a partner with the 
firm of Foley & Lardner, which co-hosted a luncheon for business and 
community leaders to meet Lipton.

The researcher, who discovered the first U.S. drug approved for dementia, 
told the small gathering that naturally occurring molecules called free 
radicals play a crucial role in brain-based diseases.

In some people, the molecules damage proteins that keep the brain running 
smoothly. The proteins become misshapen and disrupt normal brain functions.

In Alzheimer's, the brain accumulates clumps of tangled proteins or plaques 
that slowly eat away at the tissue. Patients lose their memories and 
everyday abilities. In Parkinson's, cells that make a chemical called 
dopamine stop working or die. Patients tremble, lose their balance and walk 
stiffly.

Lipton tallied the victims at more than 1 million Americans with 
Parkinson's; 500,000 with multiple sclerosis; and more than 5 million with 
Alzheimer's, at a cost of $100 billion a year. Lipton runs the Burnham 
Center for Neuroscience, Aging and Stem Cell Research.

Robyn Shelton can be reached at [log in to unmask] or 
407-420-5487.

Rayilyn Brown
Director AZNPF
Arizona Chapter National Parkinson Foundation
[log in to unmask] 

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn